Drug intelligence / Profile preview

AN0999

Development stage: Preclinical
Lead developer: Beijing Anlong Biopharmaceutical
Modality: Small Molecules
Administration: Ophthalmic

Overview

AN0999 is a preclinical-stage small molecule candidate being developed by Beijing Anlong Biomedical (Anlong Bio) for the treatment of autoimmune diseases. As of early 2024, the specific biological target and molecular mechanism of action for AN0999 have not been publicly disclosed by the developer. The asset is part of Anlong's internal pipeline, which includes both gene therapies and small molecule therapeutics aimed at addressing significant unmet needs in immunology and inflammation.

Beyond the preview

Go deeper on AN0999.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AN0999.

Explore the full profile